



## *Manufacturer's Information*

### **Test No. 22-5882: DNA Interpretation**

---

Each sample pack contained digital files consisting of electropherograms from DNA profiles of two known samples (Items 1 & 2) and two questioned samples (Items 3 & 4). Participants were requested to evaluate the electropherograms and interpret the data using their existing protocols.

**SAMPLE PREPARATION:** Item 1 was created using blood collected from a male donor. Item 2 was created using blood collected from another male donor. The Item 3 mixture was created by combining one part of blood from the Item 2 male donor, three parts of blood from a 3rd-party male donor, and one part of blood from a female donor. The Item 4 mixture was created by combining one part of blood from the Item 2 male donor and three parts of blood from the same 3rd-party male donor used in the Item 3 mixture.

**SAMPLE SET ASSEMBLY:** Once sample preparation and verification was completed, the digital upload was checked to ensure all items were accessible.

**VERIFICATION:** Laboratories that conducted predistribution testing of the electropherograms reported consistent results for all loci. All associations were consistent amongst the predistribution laboratories.

Consensus results on the following pages were determined by ensuring at least 10 participants returned results for the locus. Each allele listed was determined by ensuring that at least 75% of participants that returned data for that specific locus and item reported the same allele.

*The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.*

**Manufacturer's Information, continued**  
**Test No. 22-5882: DNA Interpretation**

<b>Amelogenin and STR Results</b>						
<i>Results compiled by predistribution laboratories and a consensus of participants.</i>						
<b>Item</b>	<b>D1S1656</b>	<b>D2S1338</b>	<b>D2S441</b>	<b>D3S1358</b>	<b>D5S818</b>	<b>D7S820</b>
	<b>D8S1179</b>	<b>D10S1248</b>	<b>D12S391</b>	<b>D13S317</b>	<b>D16S539</b>	<b>D18S51</b>
	<b>D19S433</b>	<b>D21S11</b>	<b>D22S1045</b>	<b>Amelogenin</b>	<b>CSF1PO</b>	<b>FGA</b>
	<b>Penta D</b>	<b>Penta E</b>	<b>SE33</b>	<b>TH01</b>	<b>TPOX</b>	<b>vWA</b>
	<b>DYS391</b>	<b>DYS570</b>	<b>DYS576</b>	<b>Y Indel</b>		
1	12,16	17,17	11,11	17,18	11,11	9,11
	12,14	14,16	18,20	8,12	12,13	12,16
	14,14	29,29	15,15	X,Y	12,12	20,23
	13,14	12,12	17.3,24.2	8,9.3	8,11	18,18
	10	*	*	2		
2	11,14	20,21	13,13	15,16	12,13	10,10
	13,14	13,14	15,16	11,12	11,12	13,18
	13,15.2	27,35	11,14	X,Y	8,10	25,25
	8,8	7,12	14,18	7,8	8,10	16,18
	11	*	*	2		
3	10,11,12,17.3	17,18,19	11,13,14	14,15,16,18	11,12	10,10
	12,13,14,16	12,13,14	15,18,22,25	12,12	10,11,12,13	13,15,16,17
	14,15	27,28,29	11,14,16	X,Y	11,12,13	21,23,24,25
	9,11,13	7,10,11,17	15,18,19	6,7,9.3	8,9	16,17
	10	*	*	2		
4	10,11,14,17.3	18,19,20,21	11,13,14	15,16,18	11,12,13	10,10
	13,14,16	12,13,14	15,16,22	11,12	11,12,13	13,15,16,18
	13,14,15,15.2	27,28,29,35	11,14,16	X,Y	8,10,12,13	23,25
	8,9,13	7,11,12	14,15,18	6,7,8	8,9,10	16,17,18
	10,11	*	*	2		

<b>YSTR Results</b>									
<i>Results compiled from predistribution laboratories and a consensus of participants.</i>									
<b>Item</b>	<b>DYF387S</b>	<b>DYS19</b>	<b>DYS385</b>	<b>DYS389-I</b>	<b>DYS389-II</b>	<b>DYS390</b>	<b>DYS391</b>	<b>DYS392</b>	<b>DYS393</b>
	<b>DYS437</b>	<b>DYS438</b>	<b>DYS439</b>	<b>DYS448</b>	<b>DYS449</b>	<b>DYS456</b>	<b>DYS458</b>	<b>DYS460</b>	<b>DYS481</b>
	<b>DYS518</b>	<b>DYS533</b>	<b>DYS549</b>	<b>DYS570</b>	<b>DYS576</b>	<b>DYS627</b>	<b>DYS635</b>	<b>DYS643</b>	<b>YGATAH4</b>
1	36,39	17	14,14	12	28	22	10	11	13
	16	10	11	21	28	15	16	10	24
	36	9	13	18	19	21	21	11	13
2	37,41	15	17,17	13	30	21	11	11	13
	14	11	11	21	27	15	16	10	28
	38	11	11	19	15	19	21	13	12
3	37,38	17	17,20	13	30	21	10	11	14
	14	11	11,12	19	32	15	17	10	25
	40	11	11	16	15,17	20	22	13	12
4	37,38,41	15,17	17,20	13	30	21	10,11	11	13,14
	14	11	11,12	19,21	27,32	15	16,17	10	25,28
	38,40	11	*	16,19	15,17	19,20	21,22	*	12

\* Results were not received from a minimum of 10 participants for the loci indicated.

† Additional alleles may be present depending on laboratory thresholds and/or amplification kit used.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.